Advertisement

Novartis gets FDA breakthrough status for Tafinlar, Mekinist combination

Novartis gets FDA breakthrough status for Tafinlar, Mekinist combination
From Reuters - October 22, 2017

ZURICH (Reuters) - Novartis on Monday said the U.S. Food and Drug Administration has granted breakthrough therapy status to the combination of Tafinlar and Mekinist to treat patients with BRAF V600-positive stage III melanoma following surgery.

There is a need for more effective treatment options for stage III melanoma patients at a high risk of recurrence following surgical resection, Samit Hirawat, head of global drug development at Novartis oncology unit, said in a release.

Advertisement

Continue reading at Reuters »